Data from Randomized Pilot Study, Real-World Use of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) to be Presented in Symposium at EuroPCR 2008

ous is a veryimportant and promising alternative to drug-eluting sten...Unlike drug-eluting stents Genous which is coated with an antibody...OrbusNeich designs develops manufactures and markets innovativemedi...A global company OrbusNeich is headquartered in Hong Kong and hasope...Editor's Note: OrbusNeich will display the Genous Bio-engineered Rste...

ous is a very
important and promising alternative to drug-eluting stents," said de
Winter. "EuroPCR is the ideal venue at which we can share our findings and
demonstrate the impact that the Genous technology is having on the
interventional cardiology community."

Unlike drug-eluting stents, Genous, which is coated with an antibody,
captures a patient's endothelial progenitor cells (EPCs) to accelerate the
natural healing process. EPCs circulate in the bloodstream and are involved
in the repair of blood vessels. When attracted to the surface of Genous,
EPCs rapidly form an endothelial layer over the stent that provides
protection against thrombus and minimizes restenosis.

OrbusNeich designs, develops, manufactures and markets innovative
medical devices for the treatment of vascular diseases. The company's
product portfolio includes the Genous Bio-engineered R stent, an
antibody-coated device that is the first-ever stent to capture a patient's
endothelial progenitor cells (EPCs) to accelerate the natural healing
process following placement. Other products are stents, balloons and
guiding catheters marketed under the names of Blazer(TM), R stent(TM),
Sapphire(TM), Avita(TM), Avita HP(TM), SafeCut(TM), Lumina(TM) and Saffron.

A global company, OrbusNeich is headquartered in Hong Kong and has
operations in Fort Lauderdale, Fla.; Hoevelaken, The Netherlands; Tokyo;
and Shenzhen, China. OrbusNeich, which has provided cardiology devices to
physicians through its predecessor companies since 1979, today supplies
products to interventional cardiologists in more than 60 countries. For
more information, visit http://www.OrbusNeich.com.

(Date:7/30/2015)... 30, 2015 Edwards Lifesciences Corporation (NYSE: EW ... and hemodynamic monitoring, today announced that Robert A. Ingram ... "Bob is an ardent champion for innovation in the ... have him on Edwards, board as we pursue our focused ... and CEO. "Bob has provided a valuable perspective to our ...

(Date:7/30/2015)... VIEW, Calif. , July 30, 2015 ... it will release its second quarter 2015 financial results ... 2015. In conjunction with the release, the Company ... at 5:00 p.m. Eastern Time on ... of the quarter and other business developments. ...

... , , CAMBRIDGE, Mass. , ... it has reached an agreement with the U.S. Food and Drug ... trial for Vascugel®, an investigational new drug for the prevention of ... Special Protocol Assessment (SPA) procedure. Pervasis expects to initiate the study ...

(Date:7/31/2015)... , ... July 31, 2015 , ... ... important workshop at its new True North Conference Center. The medical community, social ... the Jacksonville community may be more aligned in the effort to better understand ...

(Date:7/31/2015)... ... July 31, 2015 , ... Coco Libre announced today ... media, and VIPs at the 2015 Vans US Open of Surfing, July 25 through ... can claim “no added sugar” on the market, is a natural choice given the ...

(Date:7/31/2015)... ... , ... Ticket Down is a reliable source of authentic Hamilton tickets ... refreshing show on Broadway, look no further than Hamilton. This American musical is critically ... Circle Award, Drama Desk Award, Lucille Lortel Award, and New York Drama Critics’ Award. ...

(Date:7/31/2015)... ... July 31, 2015 , ... According to an article published ... if they could reach a consensus on the steps that need to be taken ... group reached 90 percent consensus on a series of steps that each surgeon must ...

(Date:7/31/2015)... York, New York (PRWEB) , ... ... ... renowned trial attorney Jason T. Brown’s live lecture on pharmaceutical negligence is ... July 28th, 2015 was well received with a 94% approval rating from ...

... including Parkinson's, Alzheimer's, Diffuse Lewy body disease, and ... Most commonly they become symptomatic due to a ... case of Parkinson's it is dopamine. When the ... impaired, which occurs with oxidation, the eventual results ...

... to diagnose and many a times the diagnosis is ... emerging as a promising technique for early diagnosis of ... facilitating rapid amplification of small amounts of a genome ... Urology Congress in India. Presence of even one ...

... (PPA),is a common ingredient found in many non-prescription cough ... remedies increased the risk of stroke by 23 percent. ... says, "Case reports have linked exposure to PPA to ... ,A hemorrhagic stroke results when an artery wall ruptures ...

... of India has successfully undergone left knee joint replacement by ... "The operation, which started at around 10 a.m., was completed ... satisfaction," Dr. Ranawat said at a press briefing. ``He (Mr. ... now in the recovery room. He is not on any ...

... injectable contraceptive pill has been approved by the Food ... than 99 percent effective when women get the shot ... the pill., ,Lunelle is an alternative to another ... works Like many other birth control pills as it ...

... that more than two-thirds of births in Russia are marred ... clinic is suffering health problems. , ,The number of ... 30 percent last year, said Olga Frolova, head of the ... that the decline is due to the spread of heavy ...